According to the above analyses, we hypothesized that the efficacy of MST-312 against high-STMN1-expressing HCC cells may be due to its ability to downregulate and/or inactivate STMN1 and then reverse STMN1-co-expressed gene signature. The gene discussed is STMN1; the disease is hepatocellular carcinoma.